Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by clearing amyloid plaques from the brain, the modality has been dogged by a ...

A new study shows that components found in aged blood can speed up the buildup of amyloid proteins and alter behavior in an ...

Medications like lecanemab (Leqembi) and donanemab (Kisunla) target amyloid plaques in the brain that build up due to Alzheimer’s disease. They may help slow disease progression for people in the ...

Beta-amyloid plaques are considered a hallmark of Alzheimer’s disease, but they’re not the sole cause of the disease and its symptoms. Alzheimer’s is a complicated disease that experts are still ...

This article is based on a poster originally authored by Malika Bsibsi, Catalina Gomez Puerto, Lieke Geerts, Matteo Zanella, Stefan Kostense, and Marijn Vlaming, presented at SfN 2024. The chronic ...

In the last few years, progress has been made in the fight against Alzheimer's disease with a class of therapies called ...

An estimated 50 million people worldwide have dementia, with Alzheimer's disease—accounting for more than 70%—being the representative neurodegenerative brain disorder. A Korean research team has, for ...

Higher initial amyloid levels in certain brain regions of older adults with no cognitive or psychiatric symptoms at baseline are associated with greater informant-rated but not self-rated apathy at ...

Seeding Plaques:Peter Lansbury and colleagues identified a possible mechanism for the formation of amyloid plaques in Alzheimer's disease. J.T. Jarrett, E.P. Berger, P.T. Lansbury, Jr., "The carboxy ...

Have we been wrong about what causes Alzheimer's disease? New research suggests yes. For years, the leading theory for the cause of this neurodegeneration was the accumulation of abnormal proteins in ...